32 Biosciences Unveils New Gut Microbiome Medicine Approach

CHICAGO, Sept. 11, 2024 – 32 Biosciences, also known as "Three Squared Biosciences," has officially come out of stealth mode, unveiling new tools for microbiome diagnostics and management as well as microbiome-based therapies. The company aims to revolutionize healthcare through its innovative focus on gut microbiome medicine.

Chronic diseases remain a major issue despite advances in medical research and treatment. While modern medicine has extended life expectancy, it has not necessarily improved quality of life. This is partly due to a focus on treating illness rather than preventing it. Additionally, poor dietary habits and extensive use of antibiotics have disrupted the gut microbiome, a crucial yet often overlooked element of health.

The gut microbiome is increasingly being recognized as essential for overall health, sometimes referred to as the "sixth vital organ." Disruption of this complex system, known as dysbiosis, can result in systemic inflammation, higher infection risks, and various chronic diseases. Currently, there are no standardized measures to assess the functional health of the gut microbiome.

32 Biosciences aims to fill this gap with its gut microbiome platform technologies. One of its leading assets, GB-0001, is an advanced diagnostic management tool designed to offer a standardized measure of gut microbiome health. If approved, GB-0001 would enable healthcare professionals to monitor gut health and adjust medications and nutrition accordingly, thereby improving gut microbiome health. This tool will also facilitate the development of microbiome-based therapies for disease prevention and treatment. One such therapeutic asset is CS-0003, which aims to target harmful gene expressions while fostering the growth of beneficial bacteria. Additionally, 32 Biosciences plans to introduce nutritional products designed to restore and maintain gut microbiome health.

Peter Farmakis, CEO of 32 Biosciences, stated, "We are pioneering a new approach to medicine by leveraging our advanced microbiome research to create clinically validated tools for diagnosing and addressing dysbiosis, a key factor in many diseases. Our goal is to better serve patients with limited treatment options and create significant financial value by addressing high unmet needs in large economic markets."

The company's strategy is based on research conducted by its scientific co-founders—John Alverdy, MD, and Eugene Chang, MD, from The University of Chicago, and Joseph Pierre, PhD, from the University of Wisconsin-Madison. Their innovative work in microbiome research has received $119 million in grants from the National Institutes of Health (NIH). 32 Biosciences partnered with The University of Chicago Duchossois Family Institute to develop GB-0001 and with The University of Chicago Pritzker School of Molecular Engineering for the development of CS-0003 technologies.

32 Biosciences is a healthcare firm focused on advancing gut microbiome medicine. The company is dedicated to creating diagnostic management tools and microbiome-based interventions to improve health-span by addressing the critical role of the gut microbiome in overall health. Established in 2023, 32 Biosciences was formalized as the parent company in April 2024, encompassing its wholly owned subsidiaries Covira, founded in 2018, and Gateway Biome, established in 2022.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!